Subclinical Hypothyroidism Predicted Adverse Cardiovascular Events in Patients with Ejection Fraction Preserved Heart Failure
Qiang Tan,Ming Chen,Hongmei Yang,Yao Guo,Xiaoyi Zou
DOI: https://doi.org/10.2147/tcrm.s433489
2024-04-30
Therapeutics and Clinical Risk Management
Abstract:Qiang Tan, Ming Chen, Hongmei Yang, Yao Guo, Xiaoyi Zou Department of Cardiology, Qinhuangdao First Hospital, Hebei Medical University, Qinhuangdao, Hebei Province, People's Republic of China Correspondence: Qiang Tan, Department of Cardiology, Qinhuangdao First Hospital, Hebei Medical University, Qinhuangdao, Hebei Province, People's Republic of China, Email Background: Subclinical hypothyroidism (SH) increases the risk of cardiovascular events, however the influence of SH on prognosis of ejection fraction preserved heart failure (HFpEF) is not fully understood. Methods: In this prospective observational study, patients with HFpEF were divided into euthyroidism group (n = 413) and SH group (n = 79). Patients were followed up for at least 30 months to examine the association between SH and cardiovascular events in patients with HFpEF. The primary end point was composite cardiovascular events (cardiovascular death and re-hospitalization). The patients underwent flow-mediated dilation (FMD) measurement by ultrasound in order to value endothelial function. Results: The rate of composite cardiovascular events was higher in SH group than in euthyroidism group (54.49% and 26.36%, respectively; p < 0.001). The higher risk of cardiovascular events in SH group was primarily due to a higher risk of re-hospitalization compared to euthyroidism group (45.56% and 20.58%, respectively; p < 0.001). The rate of cardiovascular death was higher in SH group than in euthyroidism group (13.92% and 5.81%, respectively; p = 0.017). Cox proportional hazards regression showed that SH (hazard ratios [HR] 1.921, 95% confidence interval [CI] 1.139– 3.240), level of TSH (HR 1.025, 95% CI 1.010– 1.054), age (HR 1.017, 95% CI 1.002– 1.034), LVEF (HR 0.975, 95% CI 0.953– 0.996), atrial fibrillation (HR 1.581, 95% CI 1.083– 2.307), eGFR (HR 0.987, 95% CI 0.978– 0.997), and NYHA cardiac function (HR 2.342, 95% CI 1.649– 3.326) were independent predictors of cardiovascular events in patients with HFpEF (all P < 0.05). Conclusion: Subclinical hypothyroidism was associated with increased cardiovascular events and death in patients with HFpEF. Keywords: subclinical hypothyroidism, ejection fraction preserved heart failure, endothelial function, flow-mediated dilation, cardiovascular events Thyroid hormone participates in several cardiovascular functions, including endothelial function, conduction system, and cardiac construction. 1 Insufficient thyroid hormone leads to ventricular arrhythmias and endothelial dysfunction. 2 Subclinical hypothyroidism is defined as elevated thyroid-stimulating hormone (TSH) levels with normal free thyroid hormone concentrations. 3 Previous studies indicated that subclinical hypothyroidism increases the risk of cardiovascular events. 4,5 Heart failure (HF) is still a main cause of morbidity and mortality all over the world. According to the left ventricular ejection fraction (LVEF), HF could be classified into HF with reduced ejection fraction (HFrEF), HF with improved ejection fraction (HFimpEF), HF with mildly reduced ejection fraction (HFmEF), and HF with preserved ejection fraction (HFpEF). 6 HFpEF is the most common type of HF in the population. As previous research suggested, 7 subclinical hypothyroidism is associated with poor prognosis of cardiovascular disease, but previous studies have not mentioned whether subclinical hypothyroidism influences prognosis in patients with heart failure. To our knowledge, there is no research to explore the association between subclinical hypothyroidism and HFpEF. The purpose of this study is to investigate whether subclinical hypothyroidism is associated with adverse prognosis in patients with HFpEF. This was a prospective observational study of patients with HFpEF who were discharged from Qinhuangdao First Hospital between September 2016 and March 2020. The diagnosis of HFpEF was made by two cardiologists on the basis of the HFpEF guidelines. 8 The inclusion criteria are as follows: (1) patients with a diagnosis of HFpEF, the criterion of HFpEF is according to ACC/AHA guidelines (LVEF ≥ 50%, evidence of spontaneous or provokable increased LV filling pressure, NT-pro BNP ≥ 220 pg/mL); (2) New York Heart Association (NYHA) class II–IV; (3) patients aged 25–85 years; and (4) signed informed consent. Exclusion criteria were: (1) patients with acute myocardial infarction; (2) patients receiving amiodarone therapies; (3) patients with thyroxine substitution therapy; (4) patients with carcinoma; (5) patients who did not have thyroid function testing; (6) patients with overt hyperthyroidism, overt hypothyroidism, low-T3 syndrome, and subclinical hyperthyroidism; and (7) patients w -Abstract Truncated-
health care sciences & services